What Otsuka Pharmaceutical does

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社) is a privately held Japanese total-healthcare company founded in 1964 and headquartered in Chiyoda-ku, Tokyo, operating as the core pharmaceutical and consumer-health subsidiary of the publicly traded Otsuka Holdings group. The company runs two business segments: (1) a Pharmaceutical business developing and commercializing prescription drugs in CNS (aripiprazole/Abilify — a dopamine D2 partial agonist with FDA approval; centanafadine for ADHD), renal (tolvaptan/Samsca/Jinarc for ADPKD), oncology, tuberculosis, and ophthalmology, plus diagnostic devices including the FDA-cleared POCone 13CO2 breath analyzer; (2) a Nutraceuticals business delivering functional beverages (Pocari Sweat isotonic drink with ion balance derived from intravenous-fluid science, Oronamin C), nutritional supplements (Calorie Mate, Nature Made, Amino Value BCAA products, EQUELLE, OS-1 oral rehydration), soy-based foods (SOYJOY), and cosmedics (InnerSignal skincare with AMP), including the 2026 launches /zeroz with Kenferol ingredient and renewed Calorie Mate Jelly.

The business model combines prescription-drug revenue (sold through hospital and clinic pharmacies via a dedicated CNS and general MR sales force) with high-volume consumer products retailed across convenience stores, supermarkets, drug stores, and the Otsuka Plus One direct e-commerce site in Japan, plus a layered international footprint that spans wholly-owned US and European pharmaceutical subsidiaries (Otsuka America Pharmaceutical, Otsuka Pharmaceutical Europe), joint ventures in China (Weiwei Food & Beverage), Taiwan (Kincha Otsuka), and Indonesia (P.T. Amerta Indah Otsuka), a 49% stake in France's ALMA S.A. mineral water group, and greenfield nutraceutical manufacturing across Thailand, Myanmar, Mexico, Vietnam, and India. Consumer-unit pricing is publicly disclosed (Pocari Sweat 500ml PET at JPY 147, Calorie Mate Jelly at JPY 220, SOYJOY bar at JPY 115) while pharmaceutical pricing follows national health-insurance drug-price schedules.

Recent strategic emphasis is on CNS and renal pipeline expansion through biotech M&A (Transcend Therapeutics, closed June 2026; Cantargia's CAN10 antibody program, September 2025), Asia-led beverage manufacturing growth, and an industry-government-academia play around heat-illness prevention anchored on Pocari Sweat scientific advisory boards in the US and Japan.

Name

Otsuka Pharmaceutical

Legal name

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社)

Website

https://otsuka.co.jp

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Otsuka Pharmaceutical, the Tokyo-based core subsidiary of Otsuka Holdings (founded 1964), develops and sells prescription drugs in CNS, renal, oncology, and tuberculosis alongside consumer nutraceutical brands such as Pocari Sweat, Calorie Mate, Nature Made, SOYJOY, and Amino Value across Japan and roughly 20 international markets.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Consumer Health Products

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Sleep, Stress & Mood Support (HLAIADAG), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

Keywords

• Prescription pharmaceuticals
• Electrolyte beverages
• Nutritional supplements
• Consumer health products
• Clinical diagnostics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices22 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Prescription pharmaceutical products: Revenue from patented and generic pharmaceutical drugs sold to healthcare providers and institutions for the treatment of CNS disorders (schizophrenia, bipolar disorder, ADHD), cardiovascular/renal diseases, cancer, and other therapeutic areas. Includes drugs like Abilify (aripiprazole), Samsca/Jinarc (tolvaptan), Deltyba, and newer pipeline candidates.
2. Consumer health beverages and supplements: Revenue from over-the-counter beverages (Pocari Sweat, Oronamin C, Pocari Sweat Ion Water), nutritional supplements (Calorie Mate, Nature Made, Amino Value, SOYJOY), and cosmedics sold through retail channels (convenience stores, supermarkets, drug stores, e-commerce) in Japan and international markets.
3. Clinical diagnostics and medical devices: Revenue from diagnostic products including the POCone 13CO2 analyzer for H. pylori detection, WT1 mRNA test kit for leukemia monitoring, urine test strips, and rapilan H. pylori antibody detection kit.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Otsuka Pharmaceutical develops, manufactures, and sells prescription pharmaceuticals (for CNS disorders, oncology, cardiovascular/renal diseases, tuberculosis) and consumer health/nutraceutical products (isotonic beverages, nutritional supplements, cosmedics). The pharmaceutical business generates revenue through patented drugs like Abilify (aripiprazole) and Samsca (tolvaptan) sold to medical institutions, while the nutraceuticals business sells functional beverages (Pocari Sweat, Oronamin C, Amino Value), nutritional supplements (Calorie Mate, Nature Made, SOYJOY), and skincare products through retail channels and e-commerce in Japan and internationally.

Product overview

Otsuka Pharmaceutical operates two core business segments: pharmaceutical business and nutraceuticals (ニュートラシューティカルズ) business. The pharmaceutical business covers CNS (中枢神経), oncology (がん), cardiology/nephrology (循環器・腎), tuberculosis (結核), and ophthalmology (眼科) with products including Abilify (aripiprazole), Samsca/Jinarc, Deltyba, and diagnostic devices. The nutraceuticals business centers on ion beverages, nutritional supplements, and cosmedics. Key product brands include Pocari Sweat (ポカリスエット) as the flagship isotonic beverage, Calorie Mate (カロリーメイト) as Japan's first nutritional supplement from 1983, Nature Made (ネイチャーメイド) supplements, Amino Value (アミノバリュー) BCAA products, SOYJOY soy bars, and various cosmedics products including InnerSignal skincare line. The company also offers functional foods under the Foods with Function Claims system and Tokuho (特定保健用食品) designations. Recent new products include /zeroz self-conditioning food with kenferol and Vivoo nutrition monitoring service.

Differentiator

Problem solved

Functional benefit

Brands

• Pocari Sweat: Ion supply beverage (electrolyte drink) for hydration, launched in 1980. Available in multiple formats including PET bottles, cans, jelly, and powder.
• Calorie Mate
• Oronamin C
• Nature Made
• SOYJOY
• Amino Value
• Equelle
• Pocari Sweat Ion Water

Products and services

• Pocari Sweat (ポカリスエット) Isotonic beverage that replenishes fluids and electrolytes lost through sweating, formulated with ion balance similar to body fluid for rapid absorption.
• Pocari Sweat Ion Water (ポカリスエット イオンウォーター) Low-calorie ion beverage with transparent taste suitable for daily hydration even when not sweating, available in multiple formats including powder.
• Pocari Sweat Jelly (ポカリスエット ゼリー) Jelly format of the ion beverage providing eating-style hydration with the same ion balance for sports consumption.
• Oronamin C Drink (オロナミンCドリンク) Carbonated nutritional drink containing vitamin C, B vitamins, amino acids, and honey, marketed as an energy drink.
• Calorie Mate (カロリーメイト) Balanced nutritional supplement providing five essential nutrients (protein, fat, carbohydrates, vitamins, minerals) launched in 1983 as Japan's first nutritional supplement.
• Calorie Mate Jelly (カロリーメイト ゼリー) Jelly format of balanced nutritional supplement with three flavors (Apple, Grapefruit, Yogurt) renewed in March 2026.
• Nature Made (ネイチャーメイド) Nutritional supplement brand featuring vitamins, minerals, omega-3, herbs, and functional foods without artificial flavors, colors, or preservatives.
• Amino Value (アミノバリュー) BCAA (branched-chain amino acid) beverage line for muscle energy and athletic performance support, available in multiple formats including drink, powder, and concentrate.
• Double Amino Value (ダブルアミノバリュー) High-concentration BCAA beverage containing 4000mg of branched-chain amino acids for top athletes.
• /zeroz (ゼロズ) Self-conditioning food product containing kenferol, a plant-derived ingredient from horseradish leaves that utilizes oxygen in the body.
• SOYJOY (ソイジョイ) Gluten-free soy bar made from whole soybeans with fruit and nuts, positioned as a low GI functional food launched in 2006.
• Vivoo (ビブー) Nutrition monitoring service using urine test strips and smartphone app to measure nutritional status with dietitian advice.
• EQUELLE (エクエル) Supplement containing equol-producing lactic acid bacteria for women's health.
• Body Mainte (ボディメンテ) Conditioning beverage drink for active lifestyles launched in 2018.
• OS-1 (オーエスワン) Oral rehydration solution for medical fluid replacement.
• Oronine (オロナイン) Skin ointment product for cuts and burns.
• InnerSignal (インナーシグナル) Skincare brand using AMP active ingredient for skin turnover and turnover promotion.
• Lactic Acid Bacteria B240 Tablets (乳酸菌B240タブレット) Probiotic supplement tablets containing lactic acid bacteria strain B240 for immune support.
• Abilify (aripiprazole) (エビリファイ) Dopamine D2 receptor partial agonist (dopamine system stabilizer) discovered by Otsuka in 1988 for treatment of schizophrenia and bipolar disorder. Marketed globally as Abilify.
• Samsca / Jinarc (tolvaptan) (サムスカ/ジンアーク) Vasopressin V2 receptor antagonist for autosomal dominant polycystic kidney disease (ADPKD) and hyponatremia. Marketed as Samsca and Jinarc.
• POCone 13CO2 Infrared Spectrophotometer FDA-approved compact infrared spectrophotometer for H. pylori infection diagnosis using the 13C-urea breath test. Compact (A4-size, ~10kg), provides results in ~2 minutes per test.

Quantifiable outcome

• Lactic acid bacterium ONRICb0240 reduced gingivitis indicator BOP% from 17.6% to 12.3% (approximately 30% reduction) in 6-week clinical study
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core.

• POCARI SWEAT Science Advisory Board (US)coreStrategic or Co-development Partner · 24 June 2026Otsuka America established the Pocari Sweat Science Advisory Board in the US to develop new guidelines for heat illness prevention in America, leveraging scientific research on hydration and electrolytes.
• National Institute for Environmental Studies and others (Heat Stroke Countermeasures Industry-Government-Academia Consortium)coreOthers · 5 June 2026Otsuka Pharmaceutical co-founded the Heat Stroke Countermeasures Industry-Government-Academia Consortium with the National Institute for Environmental Studies to develop scientific and practical solutions for reducing heat stroke risks amid climate change.
• Transcend Therapeutics (US biotech)coreStrategic or Co-development Partner · 27 March 2026Otsuka Pharmaceutical acquired a US biotech company (Transcend Therapeutics) for 110 billion yen to obtain a new drug candidate for post-traumatic stress disorder (PTSD) treatment. This follows Otsuka's pattern of acquiring companies for pipeline expansion (Visterra 2018, Junana 2024, Mindset 2023).
• Cantargia ABcoreStrategic or Co-development Partner · 1 September 2025Otsuka Pharmaceutical completed acquisition of Cantargia's CAN10 antibody program in September 2025 for 280 million SEK. Cantargia develops antibody-based treatments including nadunolimab for cancer therapy and received FDA Fast Track Designation. Partnership and acquisition strengthens Otsuka's biologics pipeline.
• Environmental Restoration and Conservation Agency (環境再生保全機構)coreOthers · 21 March 2024Otsuka Pharmaceutical entered into a cooperation agreement with the Environmental Restoration and Conservation Agency for promoting heat stroke prevention awareness and countermeasures.
• Ministry of Environment, JapancoreOthers · 24 July 2023Otsuka Pharmaceutical entered into a cooperation agreement with the Ministry of Environment for promoting heat stroke prevention. The company conducts public education campaigns, provides products, and supports heat stroke prevention research.
• ALMA S.A. (France)coreStrategic or Co-development Partner · 26 May 2008Otsuka acquired 49% of ALMA S.A., France's largest mineral water company, for 750 million euros (~1.2 trillion yen) in May 2008. ALMA produces brands including Cristaline (France's #1 mineral water), Vichy Célestin, and others across 34 factories in Europe. This was Otsuka's first European consumer business base.
• 維維食品飲料股份有限公司 (Weiwei Food & Beverage Co., Ltd.)coreStrategic or Co-development Partner · 27 April 2005Otsuka made a capital investment in Weiwei Food & Beverage in April 2005. Weiwei is China's leading soy milk company with ~70% market share. The partnership enabled Otsuka to produce and sell SOYJOY and other nutraceutical products in China through Weiwei's distribution network.
• Bristol-Myers Squibb (BMS)coreStrategic or Co-development Partner · 1 March 2005Otsuka and BMS co-developed and co-commercialized aripiprazole (Abilify) globally. Otsuka discovered and developed the compound; BMS co-promoted in the US and Europe. The partnership was responsible for Abilify becoming one of the world's top-selling pharmaceuticals. Co-development also includes DPP-4 inhibitor saxagliptin (2006) and other compounds.

Scale indicators10 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Yakult Honsha: Japanese probiotic company (Yakult probiotic drink) with proprietary lactic acid bacterium strains and 20+ years of clinical research. Directly comparable to Otsuka's ONRICb0240 probiotic and B240 Tablets franchise for immune and oral health positioning.
• Meiji Holdings: Japanese food and pharmaceutical conglomerate with nutritional supplements, dairy, and pharmaceutical divisions. Comparable as a Japanese dual-segment peer combining consumer health products (similar to Calorie Mate, Nature Made) with specialty pharmaceuticals.
• Bristol-Myers Squibb: US pharmaceutical company that co-developed and co-promoted aripiprazole (Abilify) with Otsuka globally, plus the DPP-4 inhibitor saxagliptin. The deepest direct partnership peer given the long-standing CNS franchise collaboration on Abilify.
• Suntory: Japanese beverage giant (Orangina, BOSS coffee, Suntory Tennensui, C.C. Lemon) competing directly with Pocari Sweat in the domestic sports and functional beverage category. Comparable as a Japanese consumer beverage peer with strong brand portfolio and selective international expansion.
• Eisai: Japanese pharmaceutical company with deep CNS franchise (Aricept for Alzheimer's, similar to Otsuka's Abilify CNS leadership) and consumer health products. Directly comparable to Otsuka's pharma-nutraceutical dual business model and similar Japanese heritage with global ambitions.
• Daiichi Sankyo: Major Japanese pharmaceutical company specializing in oncology and specialty care, with comparable scale and Japan-centric revenue base transitioning to global franchises. Directly comparable as a Japanese specialty pharma peer investing heavily in biologics and ADC platforms.
• Kirin Holdings: Japanese beverage and pharmaceutical holding company (Kirin beer, soft drinks, Kyowa Hakko Bio pharma) competing with Otsuka in both consumer beverages (Pocari Sweat vs Kirin functional drinks) and pharmaceutical adjacencies through Kyowa Hakko Kirin.
• Astellas Pharma: Tokyo-headquartered Japanese pharmaceutical company of similar scale focused on specialty care areas including oncology, CNS, and rare diseases. Comparable to Otsuka in business model, geographic footprint (Japan plus global), and therapeutic area focus on specialty franchises with patent-protected revenue streams.

Broad incumbents

• Taiho Pharmaceutical: Japanese specialty pharmaceutical company and Otsuka Group sister company (under Otsuka Holdings) focused on oncology. Comparable as an oncology-focused Japanese specialty pharma peer within the same corporate group, providing pipeline and therapeutic-area benchmark.
• Takeda Pharmaceutical: Largest Japanese pharmaceutical company with a broad specialty care, oncology, rare disease, and consumer health portfolio. Operates globally after the Shire acquisition. Comparable as a Japanese specialty pharma incumbent with diversified revenue streams, but materially larger than Otsuka Pharmaceutical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/otsukanc
• Facebookfacebook.com/naturemade.jp
• Instagraminstagram.com/oronaminc_official

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Otsuka Pharmaceutical